
    
      This time point was chosen because the bleeding events are maximal within the first 3 months
      after implantation.

        -  Adult patients > 18 years who need a CF-LVAD due to advanced heart failure.

        -  Functional To determine the potential indication of WilfactinÂ® in the field of CF-LVAD
           and avoid widespread use and to establish evidence-based recommendation To improve the
           knowledge of the role of VWF concentrate in bleeding and angiogenesis after CF-LVAD
           implantation and to provide some results about mechanism involved angiogenesis or
           hemostasis.
    
  